Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of KITE-753 versus axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma after first-line therapy
MOH_2026-09-10_017029Phase 3Not yet recruiting
- Sponsor
- Kite Pharma
- Start
- Aug 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing KITE-753 with Axicabtagene ciloleucel comparator (2 arms). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
KITE-753axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2026-09-10_017029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-09-10_017029.